We are monitoring the impact of COVID-19 on RNAi Drug Delivery Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1888
Share on
Share on

Global RNAi Drug Delivery Market Analysis – By Drug Delivery (Nanoparticle Drug Delivery Technology, Nucleic Acid Drug Delivery Technology, Aptamer Drug Delivery Technology and Pulmonary Drug Delivery Technology), Therapeutic Application (Infectious Diseases, Cardiology, Oncology, Neurology, Ophthalmology and Metabolic Disorders), Region - Industry Size, Share, Trends, Forecast, Growth | 2019 - 2024

Pulished: February, 2020
ID: 1888
Pages: 175

RNAi Drug Delivery Market Size & Growth (2019 - 2024)

The size of the Global RNAi Drug Delivery Market was worth USD 39.4 billion in 2019 and is expected to reach USD 131.2 billion by 2024, growing at a CAGR of 27.2 % during the forecast period 2019 - 2024.

RNAi is a defense mechanism employed by Eukaryotes to degrade exogenous genes such as viruses. It is exclusively called gene silencing. We can initiate this by injecting RNAi-based drugs into the human body which is called RNAi Drug Delivery. RNAi Drug Delivery is an emerging therapeutic method. This method is specific to the point and has fewer side effects. It is possible to cure cancer with this method by controlling gene mutation. From 2006 onwards various clinical trials are being held and people are investing billions in this market to approve and research various types of RNAi-based Drugs.

Some factors like the Increasing prevalence of chronic diseases like cancer and heart diseases and innovative Applications of the drug delivery market are driving this market. In addition, Research carried out in the RNA Therapeutic field has also amplified the growth in the Global RNA Drug Delivery Market.

The rise in account of chronic diseases such as cancer and cardiac malfunctioning are leading to a constant increase in demand for the RNAi drug delivery market across the world. Government authorities in developing countries are taking measures for providing advanced drug delivery options to all sections of people to enhance healthcare services which are fuelling the growth of the Gloval RNAi drug delivery market. Also, medical research organizations are continually putting efforts for developing effective RNA therapeutics, and an increasing number of academic research and activities are also catalysing the growth of the global RNAi drug delivery market. Other factors boosting the growth of the market are increased adoptions of innovative drug delivery technologies, enhancement of drug by improving stability. Also, it reduces the risk of side effects and other complications in patients.

But, High investment and strict regulations are some of the major restraints to this market. Delivery of RNAi Drugs to specific tissues is the key challenge faced by the market.

High costs associated with research are restraining the market and are expected to challenge the growth of the global RNAi drug delivery market. Other factors that are challenging the growth of the market are inappropriate regulations, high risk of failure, shortage of skilled professionals in drug control laboratories, and lack of proper distribution networks of RNAi drug delivery due to the inadequate infrastructure of healthcare in developing countries. Accurate delivery of RNA molecules is one of the critical challenges to the companies that are involved in the Global RNAi drug delivery market.

Increased focus of research and development activities from the private and public organizations on nanotechnology to meet the continually rising demand of the RNAi drug delivery method, is expected to be creating more growth opportunities for the market over the forecast period. Increasing economies of the countries such as UK, Canada, and highly populated countries such as China and India, where the healthcare is booming rapidly is creating a wide range of opportunities for the stakeholders and others involved in the Global RNAi drug delivery market.

Key Developments in this Market in the Recent Past:

  • Alnylam Pharmaceuticals Inc. has developed an RNA-based drug called lumasiran which can be applied for treating the PH1. The company has submitted an application under NDA to the U.S Food and drug administration. The company has received the approval of lumasiran from the FDA in Jan 2020. Also, In November 2019, Alnylam pharmaceuticals Inc. has received approval from FDA for their RNA therapeutic drug called GIVLAARI which is effectively used for treatments such as hypertension, liver and kidney diseases, genetic diseases, negative impact on the quality of life in adults diagnosed with Acute Hepatic porphyria.
  • In Jan 2020, Dicerna Pharmaceutical Inc. announced that the company has entered into a strategical partnership with Novo Nordisk for developing innovative therapies for cardiac diseases associated with liver, with the help of GalXY RNAi platform technology which is developed by Dicerna.
  • In August 2018, the FDA approved a new drug called Onpattro, which comes under a new classification of drugs called small interfering RNA treatment for polyneuropathy patients. The approval of this new drug allows the professionals to eliminate haTTR and control polyneuropathy condition by targeting the root cause in depth.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 – 2024

Segments Analysed

By Drug Delivery, Therapeutic Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Analysed

Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Tekmira Pharmaceuticals Corp, Isis Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp, Quark Pharmaceuticals Inc, Silence Therapeutics plc, Traversa Therapeutics Inc, Tacere Therapeutics Inc, Sirnaomics Inc, PhaseRx Inc

 

This research report on the Global RNAi Drug Delivery Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.

RNAi Drug Delivery Market - By Drug Delivery:

  • Nanoparticle Drug Delivery Technology
  • Nucleic Acid Drug Delivery Technology
  • Aptamer Drug Delivery Technology
  • Pulmonary Drug Delivery Technology

On the basis of drug delivery, Nanoparticle Drug Delivery is the largest sub-segment in this market because of its use in the selected delivery of drugs. However, aptamer drug delivery technology is the fastest-growing segment.

RNAi Drug Delivery Market - By Therapeutic Application:

  • Infectious Diseases
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Metabolic Disorders

Regional Analysis:

North America has the largest share in the market followed by Europe because of its high investments. However, the Asia-Pacific market is expected to increase at the highest CAGR in the following five years because of increasing investments by the major players in this region

List of key market players dominating the Global RNAi Drug Delivery Market profiled in this report are:

  1. Alnylam Pharmaceuticals Inc.
  2. Merck & Co. Inc.
  3. Access Pharmaceuticals Inc.
  4. Dicerna Pharmaceuticals Inc.
  5. Tekmira Pharmaceuticals Corp
  6. Isis Pharmaceuticals Inc.
  7. Calondo Pharmaceuticals Inc.
  8. Marina Biotech Inc.
  9. RXi Pharmaceuticals Corp
  10. Quark Pharmaceuticals Inc.
  11. Silence Therapeutics plc
  12. Traversa Therapeutics Inc.
  13. Tacere Therapeutics Inc.
  14. Sirnaomics Inc.
  15. PhaseRx Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug delivery                             

                                5.1.1 Introduction           

                                5.1.2 nanoparticle drug delivery technology        

                                5.1.3 pulmonary drug delivery technology           

                                5.1.4 nucleic acid drug delivery technology          

                                5.1.5  aptamer drug delivery technology               

                                5.1.6  Y-o-Y Growth Analysis, By Drug Delivery   

                                5.1.7  Market Attractiveness Analysis, By Drug delivery 

                                5.1.8 Market Share Analysis, By drug Delivery    

                5.2 Therapeutic Application                        

                                5.2.1 Introduction           

                                5.2.2 infectious diseases              

                                5.2.3 cardiology

                                5.2.4 oncology  

                                5.2.5 neurology

                                5.2.6 ophthalmology      

                                5.2.7 metabolic disorders            

                                5.2.8  Y-o-Y Growth Analysis, By Therapeutic Application              

                                5.2.9  Market Attractiveness Analysis, By Therapeutic Application            

                                5.2.10 Market Share Analysis, By Therapeutic Application             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Delivery

                                                6.1.3.3 By Therapeutic Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Delivery

                                                6.1.4.3 By Therapeutic Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Delivery

                                                6.1.5.3 By Therapeutic Application

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Alnylam Pharmaceuticals Inc.                             

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Merck & Co. Inc                        

                8.3 Access Pharmaceuticals Inc.                

                8.4 Dicerna Pharmaceuticals Inc.                              

                8.5 Tekmira Pharmaceuticals Corp.                          

                8.6 Isis Pharmaceuticals Inc                         

                8.7 Calondo Pharmaceuticals Inc.                             

                8.8 Marina Biotech Inc.                 

                8.9 RXi Pharmaceuticals Corp                     

                8.10 Quark Pharmaceuticals Inc                

                8.11 Silence Therapeutics plc                     

                8.12 Traversa Therapeutics Inc.                 

                8.13 Tacere Therapeutics Inc                      

                8.14 Sirnaomics Inc.                        

                8.15 PhaseRx Inc.                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global RNAi Drug Delivery Market By Region, From 2019-2024 ( USD Million )
  2. Global RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  3. Global nanoparticle drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  4. Global pulmonary drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  5. Global nucleic acid drug delivery technology  Market By Region, From 2019-2024 ( USD Million )
  6. Global aptamer drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  7. Global RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  8. Global infectious diseases Market By Region, From 2019-2024 ( USD Million )
  9. Global cardiology Market By Region, From 2019-2024 ( USD Million )
  10. Global oncology Market By Region, From 2019-2024 ( USD Million )
  11. Global neurology Market By Region, From 2019-2024 ( USD Million )
  12. Global ophthalmology Market By Region, From 2019-2024 ( USD Million )
  13. Global metabolic disorders Market By Region, From 2019-2024 ( USD Million )
  14. North America RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  15. North America nanoparticle drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  16. North America pulmonary drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  17. North America nucleic acid drug delivery technology  Market By Region, From 2019-2024 ( USD Million )
  18. North America aptamer drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  19. North America RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  20. North America infectious diseases Market By Region, From 2019-2024 ( USD Million )
  21. North America cardiology Market By Region, From 2019-2024 ( USD Million )
  22. North America oncology Market By Region, From 2019-2024 ( USD Million )
  23. North America neurology Market By Region, From 2019-2024 ( USD Million )
  24. North America ophthalmology Market By Region, From 2019-2024 ( USD Million )
  25. North America metabolic disorders Market By Region, From 2019-2024 ( USD Million )
  26. United States RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  27. United States RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  28. Canada RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  29. Canada RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  30. Europe RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  31. Europe nanoparticle drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  32. Europe pulmonary drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  33. Europe nucleic acid drug delivery technology  Market By Region, From 2019-2024 ( USD Million )
  34. Europe aptamer drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  35. Europe RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  36. Europe infectious diseases Market By Region, From 2019-2024 ( USD Million )
  37. Europe cardiology Market By Region, From 2019-2024 ( USD Million )
  38. Europe oncology Market By Region, From 2019-2024 ( USD Million )
  39. Europe neurology Market By Region, From 2019-2024 ( USD Million )
  40. Europe ophthalmology Market By Region, From 2019-2024 ( USD Million )
  41. Europe metabolic disorders Market By Region, From 2019-2024 ( USD Million )
  42. U.K. RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  43. U.K. RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  44. Germany RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  45. Germany RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  46. France RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  47. France RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  48. Italy RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  49. Italy RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  50. Spain RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  51. Spain RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  52. Asia-Pacific RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  53. Asia-Pacific nanoparticle drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  54. Asia-Pacific pulmonary drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  55. Asia-Pacific nucleic acid drug delivery technology  Market By Region, From 2019-2024 ( USD Million )
  56. Asia-Pacific aptamer drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  57. Asia-Pacific RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  58. Asia-Pacific infectious diseases Market By Region, From 2019-2024 ( USD Million )
  59. Asia-Pacific cardiology Market By Region, From 2019-2024 ( USD Million )
  60. Asia-Pacific oncology Market By Region, From 2019-2024 ( USD Million )
  61. Asia-Pacific neurology Market By Region, From 2019-2024 ( USD Million )
  62. Asia-Pacific ophthalmology Market By Region, From 2019-2024 ( USD Million )
  63. Asia-Pacific metabolic disorders Market By Region, From 2019-2024 ( USD Million )
  64. Japan RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  65. Japan RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  66. China RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  67. China RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  68. India RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  69. India RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  70. Australia RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  71. Australia RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  72. South Korea RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  73. South Korea RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  74. Latin America RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  75. Latin America nanoparticle drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  76. Latin America pulmonary drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  77. Latin America nucleic acid drug delivery technology  Market By Region, From 2019-2024 ( USD Million )
  78. Latin America aptamer drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  79. Latin America RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  80. Latin America infectious diseases Market By Region, From 2019-2024 ( USD Million )
  81. Latin America cardiology Market By Region, From 2019-2024 ( USD Million )
  82. Latin America oncology Market By Region, From 2019-2024 ( USD Million )
  83. Latin America neurology Market By Region, From 2019-2024 ( USD Million )
  84. Latin America ophthalmology Market By Region, From 2019-2024 ( USD Million )
  85. Latin America metabolic disorders Market By Region, From 2019-2024 ( USD Million )
  86. Brazil RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  87. Brazil RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  88. Argentina RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  89. Argentina RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  90. Mexico RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  91. Mexico RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  92. Rest of Latin America RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  93. Rest of Latin America RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  94. Middle East & Africa RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  95. Middle East & Africa nanoparticle drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  96. Middle East & Africa pulmonary drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  97. Middle East & Africa nucleic acid drug delivery technology  Market By Region, From 2019-2024 ( USD Million )
  98. Middle East & Africa aptamer drug delivery technology Market By Region, From 2019-2024 ( USD Million )
  99. Middle East & Africa RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  100. Middle East & Africa infectious diseases Market By Region, From 2019-2024 ( USD Million )
  101. Middle East & Africa cardiology Market By Region, From 2019-2024 ( USD Million )
  102. Middle East & Africa oncology Market By Region, From 2019-2024 ( USD Million )
  103. Middle East & Africa neurology Market By Region, From 2019-2024 ( USD Million )
  104. Middle East & Africa ophthalmology Market By Region, From 2019-2024 ( USD Million )
  105. Middle East & Africa metabolic disorders Market By Region, From 2019-2024 ( USD Million )
  106. Middle East RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  107. Middle East RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )
  108. Africa RNAi Drug Delivery Market By Drug Delivery, From 2019-2024 ( USD Million )
  109. Africa RNAi Drug Delivery Market By Therapeutic Applications, From 2019-2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample